ID 112369
Title Alternative
Non-clinical studies for oncology drug development
Author
Hayakawa, Yoshihiro Pharmaceuticals and Medical Devices Agency|University of Toyama
Kawada, Manabu Pharmaceuticals and Medical Devices Agency|Microbial Chemistry Research Foundation
Nishikawa, Hiroyoshi Pharmaceuticals and Medical Devices Agency|National Cancer Center
Ochiya, Takahiro Pharmaceuticals and Medical Devices Agency|National Cancer Center
Saya, Hideyuki Pharmaceuticals and Medical Devices Agency|Keio University
Seimiya, Hiroyuki Pharmaceuticals and Medical Devices Agency|Japanese Foundation for Cancer Research
Yao, Ryoji Pharmaceuticals and Medical Devices Agency|Japanese Foundation for Cancer Research
Hayashi, Masahiro Pharmaceuticals and Medical Devices Agency|Toranomon Hospital
Kai, Chieko Pharmaceuticals and Medical Devices Agency|The University of Tokyo
Matsuda, Akira Pharmaceuticals and Medical Devices Agency|Hokkaido University
Naoe, Tomoki Pharmaceuticals and Medical Devices Agency|Nagoya Medical Center
Ohtsu, Atsushi Pharmaceuticals and Medical Devices Agency|National Cancer Center
Okazaki, Taku Pharmaceuticals and Medical Devices Agency|Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Saji, Hideo Pharmaceuticals and Medical Devices Agency|Kyoto University
Sata, Masataka Pharmaceuticals and Medical Devices Agency|Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Sugimura, Haruhiko Pharmaceuticals and Medical Devices Agency|Hamamatsu University School of Medicine
Sugiyama, Yuichi Pharmaceuticals and Medical Devices Agency|RIKEN
Toi, Masakazu Pharmaceuticals and Medical Devices Agency|Kyoto University
Irimura, Tatsuro Pharmaceuticals and Medical Devices Agency|Juntendo University
Keywords
Animal model
cancer
drug development
oncology drug
regulatory science
Content Type
Journal Article
Description
Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.
Journal Title
Cancer Science
ISSN
13497006
Publisher
Japanese Cancer Association
Volume
107
Issue
2
Start Page
189
End Page
202
Published Date
2016-02-26
Rights
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Institute of Advanced Medical Sciences
Medical Sciences